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BACKGROUND. Semaphorins act as chemotactic cues for cell movement via their trans-
membrane receptors, plexins. Somatic missense mutations in the plexinB1 gene coupled with
overexpression of the protein frequently occur in prostate tumors, indicating a role for
plexinB1 in the pathogenesis of prostate cancer. However, the effect of semaphorin/plexin
signaling is highly context dependent and whether plexinB1 acts as an inducer or inhibitor of
prostate tumor progression in this context is not known.
METHODS. The response of prostate cancer cell lines to plexinB1 activation was assessed in
migration, invasion, proliferation and protein phosphorylation assays. Expression was
assessed by quantitative RTPCR and immunoblotting.
RESULTS. Different prostate cancer cell lines respond to Sema4D (the ligand for plexinB1) in
diverse ways. Activation of endogenous plexinB1 enhances migration, invasion and anchor-
age-independent growth of LNCaP prostate cancer cells via activation of ErbB2 and Akt. In
contrast, Sema4D-stimulation decreased the motility and proliferative capacity of PC3 cells.
LNCaP has a missense mutation (Thr1697Ala) in the plexinB1 gene while LNCaP-LN3, a
derivative of LNCaP, expresses high levels of wild-type plexinB1 only. Sema4D stimulation
increases the motility and anchorage independent growth of both cell lines, showing that these
responses are not dependent on the presence of the Thr1697Ala form of plexinB1. ErbB2 and
plexinB1 are expressed in primary prostate epithelial cells.
CONCLUSIONS. PlexinB1 signals via ErbB2 to increase the invasive phenotype of prostate
cancer cells. Both wild-type and mutant forms of plexinB1 are potential targets for anti-cancer
therapy in prostate tumors that express ErbB2. Prostate 73:1326–1335, 2013.
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INTRODUCTION
Semaphorins act as cell guidance cues through
activation of their cell surface receptors neuropilins
and plexins [1,2]. Nine plexins, divided into four
classes (A1-4, B1-3, C1, D1) [3] and 21 vertebrate
semaphorins divided into five classes, have been
identified, classified according to structure [4]. Most
class 3 semaphorins bind to a complex of neuropilin 1
or 2 and a plexin, whereas class 4 semaphorins bind to
plexins directly [5]. Plexins regulate several small
GTPases, affecting the actin cytoskeleton and motility
[6]. Plexins also interact with various receptor tyrosine
kinases. PlexinB1, a receptor for semaphorin (Sema)
4D, for example, signals via the small RhoGTPases
RhoA [7], RhoD [8], Rac [9], Rnd [10], and R-Ras [11]
and interacts with the receptor tyrosine kinases
ErbB2 [12] and c-Met [13].
Semaphorins have a role in many cancers, both
affecting angiogenesis and interacting with the tumor
cell directly [14–16]. Some semaphorins act as tumor
suppressor genes, for example expression of the
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Sema3B and 3F genes on chromosome 3p21 is lost by
deletion and promoter methylation in lung can-
cer [17,18]. Sema3F induces apoptosis and suppresses
the formation of tumors in xenografts when re-
expressed in tumor cells [19]. Other semaphorins
enhance tumor progression, for example Sema4D [20],
Sema5A [21], and Sema3E [22,23] are overexpressed in
some cancers and promote tumor growth in mouse
models. The same semaphorin may have the dual
effect of promoting tumor progression in some cancer
types and antagonizing tumor progression in other
cancer types. For example plexinB1 is overexpressed in
some ovarian, breast [24], and prostate cancers [25]
and knockdown of plexinB1 reduces metastasis in in
vivo models of breast cancer [26]. In contrast, expres-
sion of plexinB1 is lost in melanoma where it is
thought to act as a tumor suppressor gene [27,28] and
is reduced in renal cell cancer [29] and low proliferat-
ing ER positive breast cancer [30]. The role of sem-
aphorins/plexins in both normal and cancer cells is
therefore highly context dependent.
We have previously found somatic missense muta-
tions in the gene for plexinB1 in prostate cancer [25]
with an increase in mutant copy number in metastases,
and high levels of the plexinB1 protein in prostate
tumors. The mutations in plexinB1 enhance adhesion,
migration and invasion in vitro in HEK293 cells and
inhibit COS7 cell collapse [25]. The three mutations
tested inhibit the R-RasGTPase activating protein
(GAP) activity of plexinB1 and one or more inhibit
RacGTP and Rnd1 binding, resulting in a loss of
inhibition of migration. Two of the mutations tested,
including the A5359G mutation found in the prostate
cancer cell line LNCaP, increase RhoD binding. The
finding of functionally significant mutations in the
plexinB1 gene in prostate tumors and overexpression
of the plexinB1 protein suggests that plexinB1 has a
role in prostate cancer. However the mechanism by
which plexinB1 contributes to prostate cancer progres-
sion and whether it acts as an inducer or inhibitor of
tumor progression in this context is not known. Since
the effect of semaphorin/plexin signaling is highly
context dependent we sought to determine the role of
plexinB1 in prostate cancer cells specifically.
MATERIALSANDMETHODS
Cell Culture
Primary cultures of benign prostatic epithelial cells
were grown from transurethral resection of the pros-
tate. Tissue was digested overnight in L-15 medium
with 5% (v/v) fetal calf serum (FCS) and 200 U/ml
collagenase. Cells were grown in PrEGM (Clonetex)
supplemented with Bulletkit® (Cambrex). Some cul-
tures were immortalized with SV40 and htert and
grown in PrEGM medium. Prostate cancer cell lines,
all of human origin, were grown in RPMI (10% FCS).
COS-7 cells were grown in DMEM (10% FCS). The
prostate cancer cell lines were obtained from ATCC
and were STR typed to confirm their identity.
Detectionof Phosphorylated Proteins
Phosphorylated proteins were detected by western
blotting with anti-phosphorylation antibodies.
Antibodies
The following antibodies were used: anti-b-actin
(Abcam, ab6276), anti-phospho-ErbB2, anti-phospho-
Akt, Akt (R&D), ErbB2, phospho-Met (Millipore),
Sema4D and plexinB1 (ECM Biosciences), and c-Met
(c-28, Santa-Cruz).
Recombinant Sema4D
COS-7 cells transfected with Sema4D-AP or empty
vector (control) were grown in serum free medium for
72 hr. The conditioned medium was collected and
used directly or purified. Sema4D concentration was
assessed by western blotting (Supplementary Fig. 2).
Immunoprecipitation
Lysates of transfected cells were incubated with
1 mg of selective antibody for 2 hr at 4°C. The antigen–
antibody complex was incubated with Protein-G
sepharose for 2 hr, washed three times and analyzed
by immunoblotting.
RTPCR
RNA was reverse transcribed (Superscript III,
Invitrogen) then amplified for 30–32 cycles using Taq
polymerase (Thermo) and the following primers: 3S.
AGG AGT GCC TCT CAC CCA GC; 3AS. GCC TGC
TCA TCC AGC AGG TC. The amplified products
were sequenced to verify their identity.
Quantitative RTPCR was performed using Brilliant
III Ultra-Fast SYBR® Green QPCR Master Mix and the
following primers for PLXNB1: S—TCTGCTCAGTGA
CCTGGTTG, AS—CTACGGA GTCCCT CACGAAG.
The following genes were used as controls (from
qStandard): Beta-2-microglobulin (B2M): CTCTCTC-
TTTCTGGCCTGGAG, ACCCAGACACATAGCAAT-
TCAG; glyceraldehyde-3-phosphate dehydrogenase
(GAPDH): TGCACCACCAACTGCTTAGC, GGCAT-
GGACTGTGGTCATGAG; succinate dehydrogenase
complex, subunit A, flavoprotein (Fp), nuclear
gene encoding mitochondrial protein (SDHA):
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AGAAGCCCTTTGAGGAGCA, CGATCACGGGTCT-
ATATTCCAGA. Average of three experiments.
shRNA
shRNAs from Open Biosystems, target sets
RHS4533-NM_001130082 for plexinB1 and RHS4533-
NM_001005862 for ErbB2, both in pLKO.1 lentiviral
vector, were used. Virus encoding shRNA to plexinB1
or ErbB2 or non-silencing control shRNA, produced in
293FT cells, was transduced into prostate cancer cells
with polybrene (8 mg/ml). Infected cells were selected
with puromycin. Knockdown of expression was con-
firmed by Western blotting.
CellMotility
Transwell migration assays were performed using
24-well, 0.8 mm transwell chambers (BD) coated with
fibronectin on the lower side. Serum-starved cells
(2  104 per insert) were placed in the upper chamber
and serum free RPMI  Sema4D (100 ng/ml) in the
lower chamber. After 6 hr, cells on underside were
fixed, stained with crystal violet and counted.
WoundHealingAssays
Cells were grown to confluence in 24-well Essen
ImageLock Plates and uniform scratch wounds made
using a wound-making device (IncuCyte™). The rela-
tive migration of the cells was assessed by measuring
the relative wound width using an IncuCyte™ live-cell
imaging system at regular time intervals as indicated.
Cell Invasion
Serum-starved cells (6  104 cells per insert) in
DMEM were placed in the upper chamber of 24-well,
0.8-mm BD Biocoat matrigel invasion chambers (BD
Biosciences) with or without Sema4D conditioned
medium. DMEM with 10% serum was placed in the
lower chamber. The chambers were incubated at 37°C
for 24 h. Cells on the upper side were removed, and
those on the underside were fixed, stained with crystal
violet, and counted.
Anchorage IndependentGrowth
Cells (2  103 cells/ml) were grown in 0.34%
agarose in serum-free conditioned medium with or
without Sema4D, over a base agarose layer of 0.7%
agarose, for 3 weeks. Colonies were viewed down a
microscope and measured and counted.
ProliferationAssay
Proliferation in the presence of Sema4D conditioned
medium or control conditioned medium, was assessed
using a Cell Proliferation Kit II (XTT) according to
manufacturer’s instructions (Roche) using 2  103
cells per well of 96-well plate.
DNASequencing
cDNA was amplified by PCR and subjected to
Sanger sequencing as described in Ref. [25].
RESULTS
Expression of PlexinB1and Sema4D
in Prostate Cancer Cell Lines
In order to understand the role of plexinB1 in
prostate cancer we investigated the expression of
endogenous plexinB1 and Sema4D in prostate cancer
cells. Prostate cancer cell lines express plexinB1 mRNA
(Fig. 1A) and protein (Fig. 1B) with high levels of
protein expression in LNCaP, LNCaP-LN3, and VCaP
and low levels in PC3 cells. Quantitative RTPCR
showed that plexinB1 mRNA levels were significantly
higher in LNCaP-LN3 cells than in LNCaP cells from
which they were derived (Fig. 1A, ii). Sema4D is
expressed by LNCaP, LNCaP-LN3 VCaP, and DU145
(Fig. 1A and B). but not PC3.
The effect of Sema4D stimulation on cell motility is
partly dependent on which co-receptors are expressed
with plexinB1 by the responding cell. Sema4D enhan-
ces cell motility of breast cancer cell lines expressing
plexinB1 and ErbB2 and decreases motility in cells
expressing plexinB1 and c-Met and the effect is
reversed by switching expression of ErbB2 and
c-Met [31]. We assessed the levels of expression of these
receptor tyrosine kinases in prostate cells. LNCaP
and LNCaP-LN3 express high levels of ErbB2 and
negligible levels of c-Met whereas PC3 expresses
high levels of c-Met and low levels of ErbB2 and
DU145 expresses similar levels of both proteins
(Fig. 1B and Supplementary Fig. 1).
Sema4DStimulation Increases theMotility,
Invasive Capacity, andAnchorage Independent
Growthof the ProstateCancer Cell Line LNCaP
Treatment with exogenously applied Sema4D sig-
nificantly increased the motility of LNCaP cells in
transwell migration assays (Fig. 2A) and in wound
healing assays (Supplementary Fig. 3) measuring
single and collective cell migration respectively.
LNCaP cells in which plexinB1 expression had been
knocked down by two different shRNAs (Fig. 2A and
B) showed reduced motility compared to LNCaP cells
expressing a non-silencing shRNA control. The motili-
ty of cells expressing shRNA1 was reduced relative to
cells expressing non-silencing shRNA even in the
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absence of Sema4D, probably because LNCaP
expresses endogenous Sema4D (Fig. 1). The reduction
in motility of cells expressing shRNA2 was less than
for those expressing shRNA1 as some residual plex-
inB1 expression remains in shRNA2-infected cells
(Fig. 2B). The observed Sema4D-induced increase in
motility is therefore dependent on plexinB1 expres-
sion. Sema4D also increased the capacity of LNCaP
cells to invade through matrigel (Fig. 2C). A reduction
in invasive capacity was observed in LNCaP cells
in which plexinB1 expression was knocked down
(Fig. 2C).
LNCaP cells form colonies when grown in anchor-
age independent conditions, a phenotype associated
with tumorigenicity. Treatment of LNCaP with
Sema4D increased anchorage independent growth and
reducing the level of plexinB1 protein expression by
shRNA resulted in a significant decrease in anchorage
independent growth, showing that expression of plex-
inB1 is required for growth of LNCaP cells in these
conditions (Fig. 2D).
Sema4DStimulationDecreases theMotility and
Proliferationof the Prostate Cancer Cell Line PC3
In contrast to LNCaP, stimulation of PC3 cells with
Sema4D reduced cell motility in transwell assays
(Fig. 3A). Knockdown of plexinB1 expression with
shRNA (Fig. 3A, ii) inhibited this response. Stimula-
tion of DU145 cells with Sema4D had little effect on
motility (data not shown).
Sema4D also decreased the proliferation of PC3
cells under normal in vitro growth conditions (Fig. 3B,
i). Knockdown of plexinB1 expression in PC3 cells
reversed the Sema4D-induced decrease in proliferation
(Fig. 3B, ii).
Sema4DStimulation Increases theMotility and
Anchorage IndependentGrowthof the Prostate
Cancer Cell Line LNCaP-LN3
LNCaP cells are heterozygous for a missense muta-
tion (A5359G, Thr1697Ala) in the plexinB1 gene, and
express mutant and wild-type (WT) plexinB1 at a ratio
of 3:1 [25]. Exogenous expression of this mutant form
of plexinB1 in HEK293 cells increases motility relative
to WT plexinB1 [25]. To determine if the increase in
motility and invasion in LNCaP cells is dependent on
the mutant form of plexinB1, we performed motility
assays using LNCaP-LN3 [32], a derivative of LNCaP
which has lost the mutant copies of plexinB1 and
expresses WT plexinB1 only (Fig. 4A). As for LNCaP,
treatment with Sema4D increased the motility of
LNCaP-LN3 (Fig. 4B). This response was inhibited by
Fig. 1. Endogenous expression of plexinB1, Sema4D, ErbB2, and c-Met in prostate cancer cells.A: (i) Endogenous expression of plexinB1
and Sema4D mRNA in prostate cancer cell lines detected by RTPCR. ii: Endogenous expression of plexinB1 in prostate cancer cell lines
detectedbyquantitativereal timeRTPCR, P < 0.05 versus LNCaP-LN3 (Student’s t-test).B: Endogenous expression of indicatedproteins in
prostate cancercell lines,detectedbyimmunoblotting.
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knockdown of plexinB1 expression by shRNA (Fig. 4B
and C). These results suggest that activation of both
WT and mutant plexinB1 increases the motility of
LNCaP cells.
Sema4D increased the anchorage independent
growth of LNCaP-LN3 and knockdown of plexinB1
expression by shRNA resulted in a significant decrease
in anchorage independent growth, similar to LNCaP
(Fig. 4D).
Interactionof PlexinB1with ErbB2 in Prostate
CancerCell Line LNCaP
LNCaP and LNCaP-LN3 cells express high levels of
plexinB1, Sema4D and ErbB2 (Fig. 1). Since plexinB1
interacts with ErbB2 [12], Sema4D may act as a pro-
migratory cue to LNCaP cells through the plexinB1-
mediated activation of ErbB2. To test this hypothesis
we investigated whether plexinB1 interacts with ErbB2
in LNCaP cells. Co-immunoprecipitation of endoge-
nous plexinB1 with endogenous ErbB2 and vice versa
demonstrated that plexinB1 and ErbB2 physically
interact with each other in LNCaP cells (Fig. 5A).
Furthermore, stimulation of LNCaP and LNCaP-LN3
with Sema4D resulted in phosphorylation of endo-
genous ErbB2 (Fig. 5B and D) and endogenous Akt
(Fig. 5C and E), a signaling factor downstream of
ErbB2.
Sema4D-Stimulated Increase inMotility in LNCaP
Cells is Dependenton ErbB2
To determine if the increase in motility observed in
LNCaP cells in response to Sema4D stimulation is
dependent on ErbB2 signaling, motility assays were
performed on LNCaP cells in which ErbB2 expression
had been knocked down by shRNA. Knockdown of
ErbB2 expression resulted in a decrease in Sema4D-
induced motility (Fig. 5F), demonstrating that
Sema4D-induced motility in LNCaP is dependent on
ErbB2 expression.
Interaction of c-Metwith PlexinB1in PC3Cells
Sema4D/plexinB1 signaling acts as an anti-migrato-
ry cue to PC3 cells (Fig. 3A) which express high levels
Fig. 2. EffectofSema4DstimulationonLNCaPprostate cancercells.A: Sema4Dincreases themotilityofLNCaPcells.Transwellmigration
assays of LNCaP cells with or without Sema4D and of LNCaP cells expressing two different shRNAs to plexinB1 (P < 0.01 vs. LNCaP þ
Sema4D) (Student’s t-test).Bars representmeans  SE.B:KnockdownofplexinB1expression in LNCaPcellswith three different lentivirally
expressed shRNAs to plexinB1or non-silencing (NS) control shRNA; western blot with anti-plexinB1and actin antibodies.C: Knockdown
of plexinB1expression decreases the invasive capacity of LNCaP cells. Invasion assays of LNCaP cells with or without Sema4D and of LNCaP
cells expressing shRNA to plexinB1 (P < 0.05 vs.LNCaP þ Sema4D, Student’s t-test).D: Sema4D increases the capacity of LNCaP cells to
grow under anchorage independent conditions. Knockdown of plexinB1expression decreases anchorage independent growth (P < 0.05 vs
NSnoSema4D, P < 0.05vsNS þ Sema4D,Student’s t-test).
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of c-Met (Fig. 1). The opposite response of LNCaP and
PC3 to Sema4D stimulation may be accounted for by
differences in the balance of ErbB2 and c-Met expres-
sion. To determine if plexinB1 interacts with c-Met
in PC3 cells, co-immunoprecipition experiments were
performed. Endogenous c-Met co-immunoprecipitated
with endogenous plexinB1 in PC3 cells showing that
c-Met binds to plexinB1 in the PC3 cell line (Fig. 6A).
Sema4D treatment of PC3 cells did not however result
in phosphorylation of c-Met (Fig. 6B) and no evidence
for dephosphorylation of c-Met following Sema4D
treatment was found (data not shown).
Expressionof PlexinB1, Sema4D,ErbB2,
andc-Met in Primary Prostate Cells
Sema4D can act as a pro-migratory cue to prostate
cancer cell lines expressing plexinB1 and ErbB2 and
has the opposite effect in others. To establish the
expression patterns of these proteins in primary
prostate epithelial cells we performed immunoblotting
of lysates of cells from prostate tissue. We found that
plexinB1 is expressed in primary cultures of cells from
benign prostatic epithelium (Fig. 7A) and in immortal-
ized benign prostatic epithelial cells (Fig. 7B). Two of
the three primary cultures of benign prostate epithelial
cells tested expressed ErbB2, the other expressed c-Met
(Fig. 7A). All seven immortalized benign prostate
epithelial cells expressed ErbB2 and one expressed
c-Met (Fig. 7B).
DISCUSSION
The presence of mutations and high expression
levels of plexinB1 in prostate tumors points to a role
for this signaling pathway in prostate cancer. The
response of a cell to Sema4D/plexinB1 signaling is
highly context dependent, differing according to
which co-receptors are expressed by the responding
cell. The aim of this study was to determine the role of
plexinB1/Sema4D signaling in prostate cancer cells
specifically.
We found that all prostate cancer cell lines tested
and most primary prostate tissue samples express
plexinB1 and most express the ligand for plexinB1,
Sema4D. If cleaved and shed by these cells, endoge-
nous Sema4D may activate plexinB1 by an autocrine
mechanism. Sema4D may also inhibit plexinB1
Fig. 3. Effect of Sema4D stimulation on PC3 prostate cancer cells.A: Sema4Ddecreasesmotilityof PC3 cells. i:Transwellmotility assays
of PC3 cells treated with Sema4D expressing non-silencing (NS) or shRNA to plexinB1 (P < 0.05 vs. PC3 cells without Sema4D, Student’s
t-test). ii:Westernblotoflysates fromPC3cellsinfectedwithlentivirusexpressingnon-silencing(NS)orplexinB1-specific shRNA.B: Sema4D
decreases proliferation of PC3 cells. i: XTTassays of PC3 cells treated with or without Sema4D. ii: XTTassays of PC3 cells infected with
lentivirusexpressingnon-silencing (NS)or shRNAtoplexinB1, treatedwithSema4D.
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expressed in the same cell by cis inhibition as
described in ephrin, Notch and Sema6A/plexinA4
signaling systems [33]. Furthermore, the prostate
cancer cells LNCaP, LNCaP-LN3, and PC3 were
responsive to Sema4D stimulation.
Our results suggest that both mutation and over-
expression of plexinB1 contribute to prostate cancer
progression. Firstly, the related cell lines LNCaP and
LNCaP-LN3 which express mutant (Thr1697Ala) or
higher levels of wild-type plexinB1 respectively,
responded to Sema4D stimulation in a similar way.
Fig. 4. Effect of Sema4D stimulation on LNCaP-LN3 prostate
cancer cells.A:LNCaP-LN3expresseswild typeplexinB1. i: cDNA
sequence of LNCaP-LN3 (top panel) and LNCaP (bottompan-
el) around region of A5359G (Thr1697Ala) mutation (arrow). ii:
Agarose gel of PCR products digested with Bstz171. The A5359G
mutation, which destroys a Bstz171 site, is represented by the top
band (170 bp).B: Sema4D increases motility of LNCaP-LN3 cells.
Transwell migration assays of LNCaP-LN3 cells with or without
Sema4D expressing control non-silencing (NS) shRNA or 2 differ-
ent shRNAs to plexinB1 (P < 0.05, versus LNCaP-LN3(NS) þ
Sema4D, Student’s t-test). Bars representmeans  SE.C: Knock-
down of plexinB1 expression in LNCaP-LN3 cells with 2 different
lentivirally expressed shRNAs to plexinB1; western blot with
anti-plexinB1 or anti-actin antibodies. NS, non-silencing shRNA.
D: Knockdown of plexinB1 expression in LNCaP-LN3 decreases
anchorage independent growth (P < 0.05 vs. NS no Sema4D,
P < 0.05vs.NSþ Sema4DStudent’st-test).
Fig. 5. PlexinB1-ErbB2 signaling in LNCaP and LNCaP-LN3 cells.
A: PlexinB1 interacts with ErbB2 in LNCaP cells. Lysates of LNCaP
were co-immunoprecipitated with plexinB1, ErbB2, or control anti-
body and pulled down proteins were detected by Western blotting.
B: Sema4Dtreatmentinducesphosphorylationof endogenousErbB2
in LNCaPcells.LNCaPcellswere stimulated for 20 minwith control
or Sema4D conditioned medium or EGF (500 ng/ml). ErbB2 phos-
phorylationwasdetectedbyWesternblotting.C:Sema4Dtreatment
induces phosphorylation of Akt in LNCaP cells. LNCaP cells were
stimulated for 20 minwith control or Sema4D conditionedmedium
or EGF (500 ng/ml). Aktphosphorylationwas detectedby Western
blotting (i) oron an antibodyarray (ii andiii).D: Sema4Dtreatment
induces phosphorylation of endogenous ErbB2 in LNCaP-LN3 cells.
LNCaP-LN3cellswerestimulatedfor20 minwithcontrolorSema4D
conditioned medium or DHT (1 nM). ErbB2 phosphorylation was
detected by Western blotting.E: Sema4D treatment induces phos-
phorylationofAktinLNCaP-LN3cells.LNCaP-LN3cellswerestimu-
lated for 20 min with control or Sema4D conditioned medium or
DHT(1 nM).AktphosphorylationwasdetectedbyWesternblotting.
F : Knockdown of ErbB2 expression in LNCaP cells blocks Sema4D-
inducedmigration. i:Transwellmotility assayof LNCaPcells express-
ing non-silencing (NS) shRNA or two different shRNAs to ErbB2.
Migration of Sema4D-stimulated cells relative to unstimulated cells
(P < 0.01 (Student’s t-test). ii:Western blot of lysates from LNCaP
cellsexpressingnon-silencing(NS)orErbB2specific shRNAs.
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Secondly, in primary prostate cancer tissue, plexinB1
mutations were present in a low proportion of the
DNA copies analyzed [25] yet the majority of tumor
cells in each tumor showed high levels of plexinB1
protein expression.
Mutations in primary tumors were only detected
following SSCP analysis and laser capture microdis-
section [25,34], suggesting, as has been previously
found in prostate cancer, a high degree of intratumor
genetic heterogeneity, with the mutations in plexinB1
conferring a selective advantage to small clones of cells
in the primary cancers. The proportion of copies of
mutant DNA in the samples increased from primary
to lymph node and bone metastases.
The Thr1697Ala mutation found in LNCaP
increases RhoD binding to plexinB1 [35] and inhibits
the R-RasGAP activity of plexinB1 [25], promoting cell
migration in HEK293 cells. It is not known if this
mutation affects ErbB2-mediated phosphorylation of
the nearby Y1708 residue which is required for PLCg
binding and Rho activation [36]. Both overexpression
and mutation of plexinB1 is expected to result in an
increase in RhoD binding and sequestration, leading
to an increase in motility and therefore both changes
are expected to confer a competitive advantage to
prostate tumor cells.
In contrast to LNCaP and LNCaP-LN3, stimulation
of PC3 cells with Sema4D decreases cell migration and
reduces proliferation. Sema4D/plexinB1-mediated ac-
tivation of c-Met has been shown to both promote and
inhibit migration in other cell types [31,37] and to
increase or decrease c-Met phosphorylation [13,28].
PC3 cells respond to Sema4D in a similar way to
certain melanoma cells in which introduction of
plexinB1 decreases migration and proliferation and
decreases HGF induced c-Met phosphorylation [28].
PlexinB1 expression is lost in melanoma and plexinB1
acts as a tumor suppressor gene in this type of
cancer [27,28]. PC3 may exemplify a subset of prostate
tumors in which plexinB1 has a role in antagonizing
tumor progression.
Late stage prostate tumors show low level over-
expression of ErbB2 and ErbB2 expression is correlated
with poor outcome and high Gleason score [38],
although the ErbB2 gene is not amplified in prostate
cancer. Expression of ErbB2 as well as plexinB1 was
observed in all seven samples of immortalized prostate
epithelial cells and two of the primary cultures.
Androgen receptor expression, which is high in late
stage prostate cancer, suppresses the expression of c-
Met [39]. In this background of high ErbB2 expression
Fig. 6. PlexinB1 interacts with c-Met in PC3 cells.A: Lysates of
PC3 cells were co-immunoprecipitated with plexinB1, c-Met or
control antibody and pulled down proteins were detected by
Western blotting. B: Sema4D treatment does not induce c-Met
phosphorylation in PC3 cells.PC3 cellswere stimulated for 20 min
with control or Sema4D conditioned medium or HGF (50 ng/ml)
and c-MetphosphorylationwasdetectedbyWesternblotting.
Fig. 7. EndogenousexpressionofplexinB1,Sema4D,ErbB2,andc-Metinprimaryprostatecells.A:Endogenousexpressionofindicatedpro-
teins in primary cultures of benign prostatic epithelium from three different individuals.B: Endogenous protein expression in immortalized
benignprostaticepithelialcells fromsevendifferentindividuals.AR,androgenreceptor.
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and low c-Met expression in late stage prostate cancer,
overexpression and/or mutation of plexinB1 may
promote prostate cancer progression.
CONCLUSIONS
PlexinB1 signals via ErbB2 to enhance the invasive
phenotype of prostate cancer cells.
Both wild-type and mutant plexinB1 are potential
targets for anti-cancer therapy in prostate tumors that
express ErbB2.
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Supplementary Fig. 1. Endogenous expression of
ErbB2 and c-Met.
Supplementary Fig. 2. Sema4D in conditioned medi-
um.
Supplementary Fig. 3. Sema4D increases motility of
LNCaP cells in wound healing assays. i: Migration of
LNCaP cells  Sema4D, assessed by a wound healing
assay. The relative wound width measured every 4 hr
using an IncuCyte™ live-cell imaging system. ii:
Relative wound width at 52 hr, P < 0.05. iii: Images
from representative wound healing assay of LNCaP
cells at 0, 24, 48, and 72 hr.
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